Formulation Development
United States Patent & Trademark Office Grants Evoke Pharma a Formulation Patent Covering GIMOTI
Evoke Pharma, Inc. recently announced the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title Nasal Formulations of Metoclopramide.…
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform & Advancements With its In Vivo Fusogen Platform
Sana Biotechnology, Inc. recently announced data from four presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting. “Sana remains focused on improving…
Roquette Cuts Ribbon on $25-Million Pharmaceutical Innovation Center in the US
Roquette recently celebrated the grand opening of its new Pharmaceutical Innovation Center, located near Philadelphia, PA, right in the heart of the United States’ Northeastern pharmaceutical corridor…..
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology
Indaptus Therapeutics, Inc. recently announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company’s Decoy…
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial for Aging-Related Frailty in Japan
Longeveron Inc. recently announced the first patient has been treated with Lomecel-B in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan.…
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety & PTSD Stress-Related Disorders
Silo Pharma, Inc. recently announced it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety,…
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
Quotient Sciences Supports Crinetics Pharmaceuticals With Fully Integrated Pediatric Development & Clinical Testing Program
Crinetics Pharmaceuticals and Quotient Sciences have recently announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics…
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne & San Diego
New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages….
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
Tiziana Life Sciences Ltd. recently announced it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 diabetes…..
Daré Bioscience Announces Positive Safety & Acceptability Data From Phase 1 Clinical Trial That Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
Daré Bioscience, Inc. recently announced that Climacteric, the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical…
Assembly Biosciences Announces Additional Promising Data From Phase 1a Clinical Trial; Provides Pipeline Update
Assembly Biosciences, Inc. recently provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly…
Multiple Sclerosis Market to Generate Sales of $29.8 Billion by 2030
The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets (7MM*) from $18.9 billion in…
Immuneering Announces Positive Initial Phase 1 Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Immuneering Corporation recently announced positive initial pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which was shared in…
Lisata Therapeutics & Warpnine Announce First Patient Treated in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma Trial
Lisata Therapeutics, Inc. and Warpnine Incorporated recently announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and….
(e-book) The Oral Dosage Drug Delivery Market 2023
Place Your Oral Formulation In Experienced Hands Download: The Oral Dosage Drug Delivery Market. Thank you for your interest in Pii and our eBook on…
Ocugen Announces Positive Preliminary Safety & Efficacy Results From Phase 1/2 Trial of Modifier Gene Therapy Product Candidate
Ocugen, Inc. recently announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the Phase 1/2 trial to assess…
Microcarrier Market is Expected to Reach $2.9 Billion
The microcarrier industry is expected to grow significantly in the near future. This is due to the increasing demand for automation and miniaturization in various…
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
atai Life Sciences recently announced the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1…
Ocean Biomedical Announces Notice of Allowance for Patent Application for Developing “Whole New Class” of Malaria Therapeutics
Ocean Biomedical, Inc. recently announced its Scientific Co-founder and a member of its board of directors, Jonathan Kurtis, MD, PhD, received a Notice of Allowance…
